Ocugen announces positive results for COVID-19 vaccine trial for children aged two-18 years
Ocugen’s partner Bharat Biotech’s phase-II/III study of Covaxin (BBV152) in 526 children showed safety, efficacy, and superior…
Recover your password.
A password will be e-mailed to you.
Recover your password.
A password will be e-mailed to you.